BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21765901)

  • 1. EZH2 depletion blocks the proliferation of colon cancer cells.
    Fussbroich B; Wagener N; Macher-Goeppinger S; Benner A; Fälth M; Sültmann H; Holzer A; Hoppe-Seyler K; Hoppe-Seyler F
    PLoS One; 2011; 6(7):e21651. PubMed ID: 21765901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
    Ougolkov AV; Bilim VN; Billadeau DD
    Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
    Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
    Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2.
    Zhang Y; Lin C; Liao G; Liu S; Ding J; Tang F; Wang Z; Liang X; Li B; Wei Y; Huang Q; Li X; Tang B
    Oncotarget; 2015 Oct; 6(32):32586-601. PubMed ID: 26452129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage.
    Wu Z; Lee ST; Qiao Y; Li Z; Lee PL; Lee YJ; Jiang X; Tan J; Aau M; Lim CZ; Yu Q
    Cell Death Differ; 2011 Nov; 18(11):1771-9. PubMed ID: 21546904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
    Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
    Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
    Fang J; Zhang M; Li Q
    Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
    Hwang CF; Huang HY; Chen CH; Chien CY; Hsu YC; Li CF; Fang FM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):597-604. PubMed ID: 21300475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mallory-Denk bodies form when EZH2/H3K27me3 fails to methylate DNA in the nuclei of human and mice liver cells.
    French BA; Oliva J; Bardag-Gorce F; Li J; Zhong J; Buslon V; French SW
    Exp Mol Pathol; 2012 Jun; 92(3):318-26. PubMed ID: 22465358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
    Karanikolas BD; Figueiredo ML; Wu L
    Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUZ12 depletion suppresses the proliferation of gastric cancer cells.
    Cui Y; Chen J; He Z; Xiao Y
    Cell Physiol Biochem; 2013; 31(6):778-84. PubMed ID: 23735840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
    Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
    Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
    Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
    Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
    Lv Y; Yuan C; Xiao X; Wang X; Ji X; Yu H; Wu Z; Zhang J
    Oncol Rep; 2012 Jul; 28(1):147-54. PubMed ID: 22552406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.